OncoMatch/Clinical Trials/NCT07188584
Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
Is NCT07188584 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for nasopharyngeal carcinoma (npc).
In order to further verify the effectiveness of the new prevention irradiation model for low-risk areas for nasopharyngeal carcinoma under immunotherapy, our team intends to conduct a non-inferiority clinical trial. The aim is to evaluate the efficacy and safety of two treatment modalities - local region reduced-target radiotherapy versus full-target radiatiotherapy (with/without CTV2) for newly diagnosed distant metastasis nasopharyngeal carcinoma, based on the full-course immunotherapy and full-dose chemotherapy. The primary endpoints are 2-year PFS and the incidence of grade 3 or higher radiation-related adverse events. If non-inferiority is confirmed, a new standard of "immunotherapy combined with reduced-target radiotherapy" will be established, ensuring efficacy while significantly reducing toxicity, and providing a more optimal comprehensive treatment strategy for nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage TANYNANYM1, IVB (AJCC 9th edition)
Metastatic disease required
Clinical stage: TanyNanyM1, stage IVB (AJCC 9th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — first-line
adequate first-line systematic therapy (platinum-containing doublet chemotherapy + PD-1 monoclonal antibody)
Must have received: anti-PD-1 therapy — first-line
adequate first-line systematic therapy (platinum-containing doublet chemotherapy + PD-1 monoclonal antibody)
Lab requirements
Cardiac function
no grade ≥ ii coronary heart disease, arrhythmia (including qtc interval prolongation in males > 450 ms, females > 470 ms) and heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07188584 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy and anti-PD-1 therapy.
What disease stage is eligible?
Stage TANYNANYM1 or IVB is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages